GlaxoSmithKline plc (GSK) today announced results from the 'LABA' (long acting beta 2-agonist) safety study, AUSTRI(SAS115359). The study compared Advair ® Diskus ®, a combination of the LABA, ...
Sharon Bassett tries to stretch a month’s supply of GlaxoSmithKline Plc’s Advair over 60 days to save money on the asthma treatment because the U.S. lacks a cheaper generic version. An alternative ...
GSK would continue to make Advair inhalers in Zebulon if generic competition emerges this year. It also makes new asthma inhalers and two HIV drugs at its Zebulon facility. Chris Seward ...
LONDON (Reuters) - GlaxoSmithKline (GSK.L) is putting more marketing muscle behind its new lung drugs and is looking for a sales boost as top respiratory experts gather to analyse clinical trials data ...
After the FDA shot down Mylan’s generic Advair for the second time in June, executives said they addressed the “minor deficiencies” and an approval should follow in mid-October. A week into November, ...
Lannett has submitted an ANDA to the Food and Drug Administration for its strategic partner, Respirant's fluticasone propionate and salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) ...
Lannett has entered into an exclusive U.S. distribution agreement for Respirent’s generic Advair Diskus (fluticasone propionate – salmeterol xinafoate powder inhaler), which is still pending approval ...
GlaxoSmithKline is shifting its sales strategy for therapy Advair to stress increasing a treatment for chronic obstructive pulmonary disease (COPD), a new report states.Advair, a long-acting beta2 ...
Novartis’ triple combination asthma candidate QVM149 has beaten GlaxoSmithKline’s Advair in a phase 2 trial. The study linked QVM149 to statistically significant improvements in lung function, leading ...
LONDON (Reuters) - GlaxoSmithKline is likely to escape generic competition to its blockbuster lung drug Advair in the United States this year, after a second application for a cut-price equivalent ...
LONDON, Sept 22 (Reuters) - GlaxoSmithKline gave a promising glimpse on Wednesday of a planned once-daily successor to its blockbuster lung treatment Advair, with results from a small study showing it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results